Motavizumab
- 1 September 2009
- journal article
- review article
- Published by Taylor & Francis in mAbs
- Vol. 1 (5) , 439-442
- https://doi.org/10.4161/mabs.1.5.9496
Abstract
Motavizumab (MEDI-524, Numax) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations. Erratum to MotavizumabOya CingozVolume 2, Issue 5September/October 2010Keywords
This publication has 8 references indexed in Scilit:
- Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.2009
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk ChildrenThe Pediatric Infectious Disease Journal, 2009
- Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and MotavizumabPublished by Springer Nature ,2008
- Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory TractJournal of Molecular Biology, 2007
- Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus PotencyAntimicrobial Agents and Chemotherapy, 2005
- Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral NeutralizationJournal of Molecular Biology, 2005
- Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1997
- Aerosolized Ribavirin Treatment of Infants with Respiratory Syncytial Viral InfectionNew England Journal of Medicine, 1983